Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Drug Use Prevention Among Girls Through a Mother-Daughter Intervention

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00310258
First received: March 30, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted

March 30, 2006
March 30, 2006
April 2005
Not Provided
Scores on substance use behavior at posttest, and annually for 3 years after posttest.
Same as current
No Changes Posted
  • scores on mediating variables at posttest, and annually for 3 years after posttest.
  • closeness with mother
  • coping skills
  • refusal skills
  • depression (mood)
  • conflict resolution
  • problem solving
  • self-efficacy
  • body image
  • normative beliefs
Same as current
Not Provided
Not Provided
 
Drug Use Prevention Among Girls Through a Mother-Daughter Intervention
Drug Abuse Prevention: A Mother-Daughter Intervention

This study will develop and test drug use prevention strategies for low-income, minority girls. Gender-specific substance use rates, risk and protective factors, and health outcomes highlight the need for interventions aimed at girls. Girls and boys share a number of risk factors, yet some factors are more salient for one gender. Girls and boys may also be affected differently by the same risk factors. Intervention planned for this study emphasizes risk and protective factors that impact girls. Our intervention will build mother-daughter communication and closeness; enhance girls’ self-efficacy and body esteem; nurture girls’ conflict management, problem-solving, stress reduction, and refusal skills; correct perceived norms; build social supports; and establish patterns of parental monitoring and supervision. We hypothesise that girls who receive GSI will have lower 3-year follow-up rates of substance use than girls who receive no intervention.

The study will occur in three phases. In a 12-month preparation phase, we will refine and complete intervention and measurement protocols, recruit subjects and randomly assign girls and mothers to study arms, and pretest girls and mothers. A 12-month implementation phase will initiate field operations of the clinical trial, including intervention delivery, process data collection, and posttests. Follow-up in the last 36 months will involve longitudinal measurements of girls and mothers, booster session development and delivery, and data analyses.

The study has two primary and seven secondary aims.

Primary Aims:

  • 1. Develop a family-based girl-specific intervention (GSI) to prevent substance use.
  • 2. Test the efficacy of GSI.

Secondary Aims:

  • 3. Test GSI to improve mediating factors of girls’ mother-daughter affective quality, coping, refusal skills, mood management, conflict resolution, problem solving, self-efficacy, body esteem, normative beliefs, social supports, and mother-daughter communication.
  • 4. Examine the effects of mediating factors on girls’ substance use behavior.
  • 5. Test GSI to improve mothers’ use of family rituals, rules against substance use, child management, mother-daughter affective quality, and communication with their daughters.
  • 6. Examine the effects of mother’ outcomes on their daughters’ substance use behavior.
  • 7. Test the effects of dose on participants’ outcomes.
  • 8. Determine if GSI has differential outcomes related to ethnic-racial group profile.

    9. Quantify the costs of intervention development and delivery.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Adolescent Behavior
Behavioral: Drug use prevention intervention
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2000
February 2006
Not Provided

Inclusion Criteria:

  • girls ages 11 to 13 years old at pretest and their mothers who have access to a private computer

Exclusion Criteria:

-

Female
11 Years to 13 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00310258
girls & drugs, 5 R01 DA017721-02
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Steven Schinke, Ph.D. Columbia University
National Institute on Drug Abuse (NIDA)
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP